| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| QGENQiagen N.V. | 9.97B | 48.38 | 127.32 | 0.66% | 19.58% | 11.11% | 5.08% | 0.40 |
| RVTYRevvity, Inc. | 13.08B | 115.33 | 47.85 | 0.16% | 8.47% | 3.23% | 4.14% | 0.43 |
| DHRDanaher Corporation | 169.45B | 239.89 | 45.35 | -0.06% | 14.43% | 6.86% | 3.13% | 0.35 |
| TMOThermo Fisher Scientific Inc. | 234.69B | 624.65 | 37.79 | 0.05% | 15.02% | 12.84% | 3.1% | 0.66 |
| WATWaters Corporation | 23.5B | 394.59 | 36.84 | 0.07% | 20.89% | 27.84% | 2.64% | 0.93 |
| MTDMettler-Toledo International Inc. | 30.57B | 1496.61 | 36.80 | 2.22% | 21.2% | 2.83% | ||
| AAgilent Technologies, Inc. | 41.06B | 144.83 | 31.69 | 6.73% | 18.75% | 19.33% | 2.81% | 0.50 |
| TWSTTwist Bioscience Corporation | 2.53B | 41.27 | -31.75 | 20.32% | -23.51% | -17.81% | 0.16 |
| Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 2.27M | 10.77M | 25.43M | 54.38M | 90.1M | 132.33M | 203.56M | 245.11M | 312.97M | 376.57M |
| Revenue Growth % | - | 3.75% | 1.36% | 1.14% | 0.66% | 0.47% | 0.54% | 0.2% | 0.28% | 0.2% |
| Cost of Goods Sold | 9.42M | 24.02M | 32.19M | 47.43M | 61.41M | 80.62M | 119.33M | 155.38M | 179.63M | 185.57M |
| COGS % of Revenue | 4.15% | 2.23% | 1.27% | 0.87% | 0.68% | 0.61% | 0.59% | 0.63% | 0.57% | 0.49% |
| Gross Profit | -7.15M | -13.25M | -6.76M | 6.96M | 28.69M | 51.71M | 84.23M | 89.73M | 133.35M | 191M |
| Gross Margin % | -3.15% | -1.23% | -0.27% | 0.13% | 0.32% | 0.39% | 0.41% | 0.37% | 0.43% | 0.51% |
| Gross Profit Growth % | - | -0.85% | 0.49% | 2.03% | 3.12% | 0.8% | 0.63% | 0.07% | 0.49% | 0.43% |
| Operating Expenses | 36.5M | 45.23M | 63.8M | 115.81M | 168.77M | 204.44M | 319.01M | 306.89M | 354.18M | 327.26M |
| OpEx % of Revenue | 16.09% | 4.2% | 2.51% | 2.13% | 1.87% | 1.54% | 1.57% | 1.25% | 1.13% | 0.87% |
| Selling, General & Admin | 18.27M | 26.06M | 43.45M | 80.13M | 103.27M | 135.9M | 212.95M | 189.74M | 218.4M | 246.98M |
| SG&A % of Revenue | 8.05% | 2.42% | 1.71% | 1.47% | 1.15% | 1.03% | 1.05% | 0.77% | 0.7% | 0.66% |
| Research & Development | 18.23M | 19.17M | 20.35M | 35.68M | 43.01M | 69.07M | 120.31M | 106.89M | 90.85M | 80.28M |
| R&D % of Revenue | 8.03% | 1.78% | 0.8% | 0.66% | 0.48% | 0.52% | 0.59% | 0.44% | 0.29% | 0.21% |
| Other Operating Expenses | 73K | -55K | -121K | -265K | 22.5M | -534K | -14.24M | 10.26M | 44.93M | 0 |
| Operating Income | -43.66M | -58.48M | -70.56M | -108.85M | -140.08M | -152.73M | -234.78M | -217.16M | -220.83M | -136.26M |
| Operating Margin % | -19.24% | -5.43% | -2.77% | -2% | -1.55% | -1.15% | -1.15% | -0.89% | -0.71% | -0.36% |
| Operating Income Growth % | - | -0.34% | -0.21% | -0.54% | -0.29% | -0.09% | -0.54% | 0.08% | -0.02% | 0.38% |
| EBITDA | -39.43M | -53.46M | -64.83M | -102.54M | -133.4M | -142.98M | -218.26M | -187.85M | -189.4M | -111.41M |
| EBITDA Margin % | -17.38% | -4.97% | -2.55% | -1.89% | -1.48% | -1.08% | -1.07% | -0.77% | -0.61% | -0.3% |
| EBITDA Growth % | - | -0.36% | -0.21% | -0.58% | -0.3% | -0.07% | -0.53% | 0.14% | -0.01% | 0.41% |
| D&A (Non-Cash Add-back) | 4.23M | 5.02M | 5.73M | 6.31M | 6.68M | 9.75M | 16.51M | 29.31M | 31.43M | 24.85M |
| EBIT | -43.34M | -58.13M | -69.68M | -106.08M | -138.76M | -153.66M | -228.19M | -203.46M | -208.14M | -76.95M |
| Net Interest Income | -505K | -493K | -314K | 1.74M | 712K | 68K | 2.98M | 14.36M | 15.31M | 11.36M |
| Interest Income | 241K | 412K | 999K | 3.03M | 1.5M | 435K | 3.06M | 14.37M | 15.34M | 11.36M |
| Interest Expense | 746K | 905K | 1.31M | 1.29M | 787K | 367K | 80K | 5K | 29K | 0 |
| Other Income/Expense | -432K | -548K | -435K | 1.47M | 530K | -1.3M | 6.5M | 13.69M | 12.66M | 59.31M |
| Pretax Income | -44.09M | -59.03M | -70.99M | -107.38M | -139.55M | -154.03M | -228.27M | -203.47M | -208.17M | -76.95M |
| Pretax Margin % | -19.43% | -5.48% | -2.79% | -1.97% | -1.55% | -1.16% | -1.12% | -0.83% | -0.67% | -0.2% |
| Income Tax | 0 | 280K | 242K | 292K | 382K | -1.93M | -10.41M | 1.15M | 560K | 719K |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 0.99% | 0.95% | 1.01% | 1% | 1.01% |
| Net Income | -44.09M | -59.31M | -71.24M | -107.67M | -139.93M | -152.1M | -217.86M | -204.62M | -208.73M | -77.67M |
| Net Margin % | -19.43% | -5.51% | -2.8% | -1.98% | -1.55% | -1.15% | -1.07% | -0.83% | -0.67% | -0.21% |
| Net Income Growth % | - | -0.35% | -0.2% | -0.51% | -0.3% | -0.09% | -0.43% | 0.06% | -0.02% | 0.63% |
| Net Income (Continuing) | -44.09M | -59.31M | -71.24M | -107.67M | -139.93M | -152.1M | -217.86M | -204.62M | -208.73M | -77.67M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -2.35 | -3.16 | -2.68 | -3.92 | -3.57 | -3.15 | -4.04 | -3.60 | -3.60 | -1.30 |
| EPS Growth % | - | -0.34% | 0.15% | -0.46% | 0.09% | 0.12% | -0.28% | 0.11% | 0% | 0.64% |
| EPS (Basic) | -2.35 | -3.16 | -2.68 | -3.92 | -3.57 | -3.15 | -4.04 | -3.60 | -3.60 | -1.30 |
| Diluted Shares Outstanding | 18.78M | 18.78M | 26.61M | 27.46M | 39.19M | 48.25M | 53.88M | 56.88M | 58.02M | 59.81M |
| Basic Shares Outstanding | 18.78M | 18.78M | 26.61M | 27.46M | 39.19M | 48.25M | 53.88M | 56.88M | 58.02M | 59.81M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 59.04M | 67.87M | 95.67M | 160.13M | 334.87M | 546.5M | 596.48M | 424.26M | 346.78M | 332.97M |
| Cash & Short-Term Investments | 55.92M | 62.2M | 80.76M | 138.11M | 290M | 477.86M | 504.97M | 336.41M | 276.4M | 232.43M |
| Cash Only | 28.6M | 31.23M | 80.76M | 46.73M | 93.67M | 465.83M | 378.69M | 286.47M | 226.32M | 183.05M |
| Short-Term Investments | 27.32M | 30.98M | 0 | 91.37M | 196.34M | 12.03M | 126.28M | 49.94M | 50.08M | 49.38M |
| Accounts Receivable | 723K | 2.35M | 5.42M | 12.1M | 25.43M | 28.55M | 40.29M | 44.06M | 34.9M | 57.02M |
| Days Sales Outstanding | 116.3 | 79.53 | 77.79 | 81.23 | 103 | 78.74 | 72.25 | 65.62 | 40.7 | 55.27 |
| Inventory | 1.23M | 1.83M | 6.03M | 7.33M | 12.29M | 31.8M | 39.31M | 32.06M | 24.08M | 28.31M |
| Days Inventory Outstanding | 47.58 | 27.76 | 68.35 | 56.41 | 73.05 | 143.97 | 120.23 | 75.32 | 48.93 | 55.68 |
| Other Current Assets | 0 | 0 | 3.47M | 0 | 951K | 0 | 0 | 11.72M | 11.4M | 15.2M |
| Total Non-Current Assets | 17.42M | 17.79M | 20.12M | 26.86M | 64.01M | 155.6M | 364.9M | 352.15M | 267.55M | 308.89M |
| Property, Plant & Equipment | 14.62M | 14.83M | 12.33M | 20.84M | 59.16M | 105.7M | 214.39M | 203.36M | 161.35M | 151.66M |
| Fixed Asset Turnover | 0.16x | 0.73x | 2.06x | 2.61x | 1.52x | 1.25x | 0.95x | 1.21x | 1.94x | 2.48x |
| Goodwill | 1.14M | 1.14M | 1.14M | 1.14M | 1.14M | 22.43M | 85.81M | 85.81M | 85.81M | 82.19M |
| Intangible Assets | 1.13M | 920K | 712K | 508K | 307K | 18.26M | 59.74M | 54.48M | 14.48M | 13.43M |
| Long-Term Investments | 322K | 202K | 579K | 579K | 0 | 0 | 0 | 0 | 0 | 54.34M |
| Other Non-Current Assets | 536K | 896K | 5.94M | 4.38M | 3.4M | 9.2M | 4.96M | 8.49M | 5.91M | 7.28M |
| Total Assets | 76.46M | 85.66M | 115.79M | 186.99M | 398.88M | 702.1M | 961.38M | 776.4M | 614.32M | 641.86M |
| Asset Turnover | 0.03x | 0.13x | 0.22x | 0.29x | 0.23x | 0.19x | 0.21x | 0.32x | 0.51x | 0.59x |
| Asset Growth % | - | 0.12% | 0.35% | 0.61% | 1.13% | 0.76% | 0.37% | -0.19% | -0.21% | 0.04% |
| Total Current Liabilities | 8.68M | 9.48M | 18.54M | 30.35M | 36.03M | 63.05M | 90.66M | 73.32M | 71.01M | 91.41M |
| Accounts Payable | 2.34M | 2.85M | 7.53M | 9.76M | 4.83M | 14.9M | 20.09M | 14.05M | 1.63M | 11.09M |
| Days Payables Outstanding | 90.54 | 43.29 | 85.4 | 75.11 | 28.71 | 67.46 | 61.46 | 33.01 | 3.31 | 21.82 |
| Short-Term Debt | 1.37M | 0 | 2.5M | 3.33M | 3.33M | 1.55M | 0 | 0 | 0 | 13.82M |
| Deferred Revenue (Current) | 1000K | 0 | 1000K | 1000K | 0 | 1000K | 1000K | 0 | 1000K | 0 |
| Other Current Liabilities | 353K | 3.16M | 3.1M | 817K | 2.61M | 28.42M | 39.62M | 18.56M | 34.61M | 66.49M |
| Current Ratio | 6.80x | 7.16x | 5.16x | 5.28x | 9.29x | 8.67x | 6.58x | 5.79x | 4.88x | 3.64x |
| Quick Ratio | 6.66x | 6.97x | 4.84x | 5.03x | 8.95x | 8.16x | 6.15x | 5.35x | 4.54x | 3.33x |
| Cash Conversion Cycle | 73.34 | 64 | 60.75 | 62.53 | 147.33 | 155.26 | 131.02 | 107.93 | 86.32 | 89.13 |
| Total Non-Current Liabilities | 144.4M | 209.54M | 298.68M | 4.56M | 26.59M | 58.22M | 81.33M | 79.65M | 70.63M | 77.5M |
| Long-Term Debt | 9.81M | 9.15M | 7.22M | 4.4M | 1.4M | 0 | 0 | 0 | 0 | 61.75M |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 24.84M | 53.16M | 81.27M | 79.17M | 70.22M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 134.58M | 200.38M | 291.46M | 158K | 351K | 5.07M | 60K | 475K | 407K | 15.75M |
| Total Liabilities | 153.07M | 219.01M | 317.21M | 34.91M | 62.62M | 121.28M | 171.99M | 152.97M | 141.63M | 168.9M |
| Total Debt | 11.18M | 9.15M | 9.72M | 7.73M | 35.98M | 62.92M | 94.91M | 94.07M | 85.03M | 75.57M |
| Net Debt | -17.41M | -22.07M | -71.04M | -39M | -57.69M | -402.91M | -283.77M | -192.4M | -141.29M | -107.48M |
| Debt / Equity | - | - | - | 0.05x | 0.11x | 0.11x | 0.12x | 0.15x | 0.18x | 0.16x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -58.52x | -64.62x | -53.74x | -84.12x | -177.99x | -416.15x | -2934.70x | -43431.80x | -7614.86x | - |
| Total Equity | -76.61M | -133.36M | -201.42M | 152.08M | 336.26M | 580.82M | 789.38M | 623.43M | 472.69M | 472.96M |
| Equity Growth % | - | -0.74% | -0.51% | 1.76% | 1.21% | 0.73% | 0.36% | -0.21% | -0.24% | 0% |
| Book Value per Share | -4.08 | -7.10 | -7.57 | 5.54 | 8.58 | 12.04 | 14.65 | 10.96 | 8.15 | 7.91 |
| Total Shareholders' Equity | -76.61M | -133.36M | -201.42M | 152.08M | 336.26M | 580.82M | 789.38M | 623.43M | 472.69M | 472.96M |
| Common Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | -80.31M | -139.62M | -210.85M | -318.52M | -458.45M | -610.55M | -828.42M | -1.03B | -1.24B | -1.32B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 9K | 33K | 87K | 181K | 87K | 546K | -1.84M | -756K | -522K | -627K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sep 2016 | Sep 2017 | Sep 2018 | Sep 2019 | Sep 2020 | Sep 2021 | Sep 2022 | Sep 2023 | Sep 2024 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -38.59M | -51.3M | -66.16M | -87.94M | -142.25M | -112.24M | -124.39M | -142.47M | -64.09M | -47.63M |
| Operating CF Margin % | -17.01% | -4.76% | -2.6% | -1.62% | -1.58% | -0.85% | -0.61% | -0.58% | -0.2% | -0.13% |
| Operating CF Growth % | - | -0.33% | -0.29% | -0.33% | -0.62% | 0.21% | -0.11% | -0.15% | 0.55% | 0.26% |
| Net Income | -44.09M | -59.31M | -71.24M | -107.67M | -139.93M | -152.1M | -217.86M | -204.62M | -208.73M | -77.67M |
| Depreciation & Amortization | 4.23M | 5.02M | 5.73M | 6.11M | 6.68M | 9.75M | 16.51M | 29.31M | 31.43M | 24.85M |
| Stock-Based Compensation | 857K | 1.89M | 2.96M | 11.17M | 17.1M | 37M | 79.66M | 30.28M | 50.92M | 0 |
| Deferred Taxes | -68K | 768K | 42K | -1.06M | -214K | 0 | 0 | -410K | 0 | 0 |
| Other Non-Cash Items | 238K | 458K | 562K | 515K | -707K | 2.49M | 2.66M | 3.98M | 46.86M | 17.8M |
| Working Capital Changes | 240K | -129K | -4.22M | 3M | -25.18M | -9.38M | -5.36M | -1.01M | 15.41M | -12.61M |
| Change in Receivables | -702K | -1.62M | -3.07M | -6.68M | -14.27M | -2.2M | -9.62M | -4.32M | 8.44M | -22.38M |
| Change in Inventory | -1.23M | -599K | -4.2M | -1.3M | -4.96M | -19.49M | -7.54M | 7.24M | 7.99M | -4.23M |
| Change in Payables | 466K | 560K | 3.76M | 3.28M | -5.51M | 8.54M | 7.38M | -2.51M | -11.8M | 9.33M |
| Cash from Investing | -33.34M | -9.87M | 26.87M | -104.81M | -114.65M | 156.16M | -232.93M | 50.61M | -3.07M | -24.76M |
| Capital Expenditures | -6.23M | -6.59M | -3.69M | -14.76M | -9.87M | -27.06M | -101.86M | -27.78M | -5.08M | -28M |
| CapEx % of Revenue | 2.75% | 0.61% | 0.15% | 0.27% | 0.11% | 0.2% | 0.5% | 0.11% | 0.02% | 0.07% |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 174K | 120K | -434K | -90.05M | -104.78M | 0 | -5.75M | -5.86M | 0 | 0 |
| Cash from Financing | 69.65M | 63.8M | 88.82M | 158.58M | 303.73M | 329.18M | 270.53M | 911K | 6.89M | 28.54M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 62.42M | 205K | -2.03M | 4.87M | 13.92M | 19.5M | 10.02M | 5.32M | 10.87M | 15M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -44.82M | -57.9M | -69.85M | -102.69M | -152.12M | -139.31M | -226.24M | -170.25M | -69.17M | -75.63M |
| FCF Margin % | -19.75% | -5.38% | -2.75% | -1.89% | -1.69% | -1.05% | -1.11% | -0.69% | -0.22% | -0.2% |
| FCF Growth % | - | -0.29% | -0.21% | -0.47% | -0.48% | 0.08% | -0.62% | 0.25% | 0.59% | -0.09% |
| FCF per Share | -2.39 | -3.08 | -2.63 | -3.74 | -3.88 | -2.89 | -4.20 | -2.99 | -1.19 | -1.26 |
| FCF Conversion (FCF/Net Income) | 0.88x | 0.86x | 0.93x | 0.82x | 1.02x | 0.74x | 0.57x | 0.70x | 0.31x | 0.61x |
| Interest Paid | 391K | 702K | 751K | 779K | 438K | 167K | 9K | 0 | 0 | 0 |
| Taxes Paid | 14K | 6K | 179K | 291K | 172K | 101K | 246K | 420K | 344K | 0 |
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | - | -70.8% | -57.31% | -33.17% | -31.8% | -28.97% | -38.08% | -16.43% |
| Return on Invested Capital (ROIC) | - | - | - | -72.19% | -53.65% | -50.18% | -51.52% | -34.78% | -43.45% | -29.33% |
| Gross Margin | -315.2% | -123.09% | -26.59% | 12.8% | 31.85% | 39.08% | 41.38% | 36.61% | 42.61% | 50.72% |
| Net Margin | -1943.06% | -550.85% | -280.16% | -197.98% | -155.31% | -114.94% | -107.02% | -83.48% | -66.69% | -20.63% |
| Debt / Equity | - | - | - | 0.05x | 0.11x | 0.11x | 0.12x | 0.15x | 0.18x | 0.16x |
| Interest Coverage | -58.52x | -64.62x | -53.74x | -84.12x | -177.99x | -416.15x | -2934.70x | -43431.80x | -7614.86x | - |
| FCF Conversion | 0.88x | 0.86x | 0.93x | 0.82x | 1.02x | 0.74x | 0.57x | 0.70x | 0.31x | 0.61x |
| Revenue Growth | - | 374.53% | 136.16% | 113.89% | 65.67% | 46.87% | 53.83% | 20.41% | 27.69% | 20.32% |
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Ngs Tools | - | - | 72.67M | 99.31M | 123.71M | 169.13M | 208.1M |
| Ngs Tools Growth | - | - | - | 36.67% | 24.56% | 36.72% | 23.05% |
| Synthetic Genes | 26.71M | 35.19M | 38.96M | 61.51M | 73.54M | 92.68M | 113.6M |
| Synthetic Genes Growth | - | 31.75% | 10.72% | 57.86% | 19.56% | 26.02% | 22.58% |
| Antibody Discovery | - | - | - | 24.17M | 23.17M | 20.33M | 23.45M |
| Antibody Discovery Growth | - | - | - | - | -4.13% | -12.27% | 15.37% |
| Oligo Pools | 4.59M | 4.54M | 8.04M | 12.42M | 14.49M | 16.91M | 20.23M |
| Oligo Pools Growth | - | -1.07% | 76.88% | 54.55% | 16.62% | 16.68% | 19.66% |
| Dna And Biopharma Libraries | - | - | 12.66M | 6.15M | 10.2M | 13.93M | 11.18M |
| Dna And Biopharma Libraries Growth | - | - | - | -51.44% | 65.90% | 36.58% | -19.73% |
| NGS Tools | 21.04M | 44.02M | - | - | - | - | - |
| NGS Tools Growth | - | 109.17% | - | - | - | - | - |
| DNA And Biopharma Libraries | - | 6.35M | - | - | - | - | - |
| DNA And Biopharma Libraries Growth | - | - | - | - | - | - | - |
| DNA Libraries | 2.04M | - | - | - | - | - | - |
| DNA Libraries Growth | - | - | - | - | - | - | - |
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Americas | - | 1.08M | 77.91M | 122.47M | 151.26M | 193.88M | 225.58M |
| Americas Growth | - | - | 7087.18% | 57.20% | 23.51% | 28.18% | 16.35% |
| EMEA | 14.69M | 25.82M | - | 62.08M | 71.39M | 92.57M | 124.24M |
| EMEA Growth | - | 75.75% | - | - | 15.00% | 29.67% | 34.22% |
| Asia Pacific | 2.76M | 5.12M | 10.3M | 19.01M | 22.46M | 26.52M | 26.75M |
| Asia Pacific Growth | - | 85.26% | 101.37% | 84.60% | 18.11% | 18.11% | 0.86% |
| E M E A | - | - | 44.12M | - | - | - | - |
| E M E A Growth | - | - | - | - | - | - | - |
| UNITED STATES | 35.94M | 58.08M | - | - | - | - | - |
| UNITED STATES Growth | - | 61.62% | - | - | - | - | - |
| North America | 996K | - | - | - | - | - | - |
| North America Growth | - | - | - | - | - | - | - |
Twist Bioscience Corporation (TWST) reported $362.3M in revenue for fiscal year 2025. This represents a 15866% increase from $2.3M in 2016.
Twist Bioscience Corporation (TWST) grew revenue by 20.3% over the past year. This is strong growth.
Twist Bioscience Corporation (TWST) reported a net loss of $85.2M for fiscal year 2025.
Twist Bioscience Corporation (TWST) has a return on equity (ROE) of -16.4%. Negative ROE indicates the company is unprofitable.
Twist Bioscience Corporation (TWST) had negative free cash flow of $68.7M in fiscal year 2025, likely due to heavy capital investments.